Herb G Bull, Age 79649 Maple St, Westfield, NJ 07090

Herb Bull Phones & Addresses

649 Maple St, Westfield, NJ 07090 (908) 232-8685

Union, NJ

234 Jefferson Ave, Westfield, NJ 07090 (908) 232-8685

Social networks

Herb G Bull

Linkedin

Mentions for Herb G Bull

Herb Bull resumes & CV records

Resumes

Herb Bull Photo 10

Herb Bull

Publications & IP owners

Us Patents

Affinity Chromatography Matrix Useful In Purifying Interleukin-1.Beta. Converting Enzyme

US Patent:
5278061, Jan 11, 1994
Filed:
Aug 16, 1991
Appl. No.:
7/746685
Inventors:
Herb G. Bull - Westfield NJ
Kevin T. Chapman - Scotch Plains NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C12N 948
A23J 100
US Classification:
435212
Abstract:
Affinity chromatography matrices are disclosed which are useful in purifying interleukin-1. beta. converting enzyme (ICE) from crude or partially purified cell lysate preparations. The chromatographic matrices comprise a specific ICE inhibitor of Formula I which is attached to an affinity column support by means of a bifunctional spacer. ##STR1##.

Treatment Of Hyperandrogenic Conditions

US Patent:
5756480, May 26, 1998
Filed:
Oct 24, 1996
Appl. No.:
8/738546
Inventors:
Herb G. Bull - Westfield NJ
Georgianna Harris - Tinton Falls NJ
Robert W. Myers - Cresskill NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C07H 1904
C07H 19048
A61K 31705
US Classification:
514 47
Abstract:
The invention concerns the treatment of hyperandrogenic conditions in humans by the formation of a novel mechanism-based irreversible inhibitor of human 5. alpha. -reductase enzymes from 3-oxo-4-oxa end 4-thiasteroids having a 1,2-double bond and the pyridine-nucleotide cofactor of the 5. alpha. -reductase enzyme, NADPH. The invention further relates to the isolated inhibitor-cofactor complex.

Irreversible Inhibition Of Human 5.Alpha.-Reductase

US Patent:
5962442, Oct 5, 1999
Filed:
May 5, 1997
Appl. No.:
8/836341
Inventors:
Herb G. Bull - Westfield NJ
Georgianna S. Harris - Tinton Falls NJ
Assignee:
Merck & Co., INc. - Rahway NJ
International Classification:
A01N 4500
US Classification:
514169
Abstract:
The invention concerns the treatment of hyderandrogenic conditions in humans by the formation of a novel mechanism-based irreversible inhibitor of human 5. alpha. -reductase enzymes from 3-oxo-4-azasteroids having a 1,2-double bond and the pyridine-nucleotide cofactor of the 5. alpha. -reductase enzyme, NADPH. Until the present invention, it was not know or predicted that 3-oxo-4-azasteroids having 1,2-double bond would form a complex with NADPH by the mechanism of 5. alpha. -reductase in vivo. The invention further relates to the novel inhibitor-cofactor complex and pharmaceutical compositions containing the complex.

Treatment Of Hyperandrogenic Conditions

US Patent:
5656613, Aug 12, 1997
Filed:
Jan 4, 1995
Appl. No.:
8/368513
Inventors:
Herb G. Bull - Westfield NJ
Georgianna S. Harris - Tinton Falls NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 3170
US Classification:
514 47
Abstract:
The invention concerns the treatment of hyperandrogenic conditions in humans by the formation of a novel mechanism-based irreversible inhibitor of human 5. alpha. -reductase enzymes from 3-oxo-4-azasteroids having a 1,2-double bond and the pyridine-nucleotide cofactor of the 5. alpha. -reductase enzyme, NADPH. Until the present invention, it was not known or predicted that 3-oxo-4-azasteroids having a 1,2-double bond would form a complex with NADPH by the mechanism of 5. alpha. -reductase in vivo. The invention further relates to the novel inhibitor-cofactor complex and pharmaceutical compositions containing the complex.

Treatment Of Hyperandrogenic Conditions

US Patent:
5932559, Aug 3, 1999
Filed:
Apr 23, 1998
Appl. No.:
9/051948
Inventors:
Herb G. Bull - Westfield NJ
Georgianna Harris - Tinton Falls NJ
Robert W. Myers - Cresskill NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 31505
C07D47102
US Classification:
514 47
Abstract:
The invention concerns the treatment of hyperandrogenic conditions in humans by the formation of a novel mechanism-based irreversible inhibitor of human 5. alpha. -reductase enzymes from 3-oxo-4-oxa and 4-thiasteroids having a 1,2-double bond and the pyridine-nucleotide cofactor of the 5. alpha. -reductase enzyme, NADPH. The invention further relates to the isolated inhibitor-cofactor complex.

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.